Disposition_of_high-dose_methotrexate_in_an_obese_cancer_patient._The_disposition_of_many_drugs_in_obesity_is_altered,_although_little_is_known_of_the_effect_of_obesity_on_the_pharmacokinetics_of_anti-cancer_drugs._In_this_report_the_authors_describe_the_pharmacokinetics_of_high-dose_methotrexate_in_an_obese_woman_(184%_ideal_body_weight)_with_osteosarcoma._For_this_patient,_both_the_volume_of_distribution_at_steady-state_(0.398_l/kg)_and_systemic_clearance_(0.0956_l/h/kg)_of_methotrexate_were_increased_compared_with_values_observed_in_adult_patients_with_osteosarcoma._The_terminal_elimination_half-life_(9.29_hours)_of_methotrexate_was_similar_to_other_reported_values_in_adult_patients,_thus_indicating_that_increases_in_methotrexate_volume_of_distribution_and_clearance_may_offset_each_other_in_obesity._Based_on_the_experience_gained_from_this_patient,_the_authors_suggest_that_renal_function_and_methotrexate_serum_concentrations_should_be_monitored_in_obese_patients_receiving_high-dose_methotrexate_with_leucovorin_rescue.